SCHEMBL4876400

SCHEMBL4876400

CC(=O)Nc1nc(CCc2ccc(NC(NC(=O)O)(N(C(=O)O)C(C)(C)C)C(C)(C)C)cc2)c(C(=O)Nc2cccnc2)s1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.38
PPARG P37231 4/20 0.38
NCOA2 Q15596 4/20 0.38
NCOA1 Q15788 4/20 0.38
MAPT P10636 4/20 0.38
KDM4E B2RXH2 3/20 0.38
HPGD P15428 3/20 0.38
ALDH1A1 P00352 5/20 0.38
MEN1 O00255 3/20 0.38
NCOA3 Q9Y6Q9 2/20 0.38
NAMPT P43490 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
LMNA P02545 1/20 0.38
GAA P10253 1/20 0.38
HTT P42858 1/20 0.38
TRPV1 Q8NER1 7/20 0.37
PIK3CG P48736 2/20 0.36
SLC2A1 P11166 1/20 0.35
RAB9A P51151 3/20 0.35
NPC1 O15118 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4985430 0.92 AOC3 (0.39) KMT2AMAPTKDM4EHPGDALDH1A1
SCHEMBL4985031 0.91 ALDH1A1 (0.42) KMT2AMAPTHPGDALDH1A1MEN1
SCHEMBL4871391 0.88 AOC3 (0.39) AOC3
SCHEMBL4985599 0.86 AOC3 (0.43) ALDH1A1SMN1; SMN2RAB9ANPC1AOC3
SCHEMBL4991741 0.86 AOC3 (0.45) KMT2AMAPTKDM4EALDH1A1MEN1
SCHEMBL4988080 0.86 NAMPT (0.36) NAMPTAOC3
SCHEMBL4864969 0.85 SCD (0.42) KMT2AMAPTALDH1A1MEN1SMN1; SMN2
SCHEMBL4986164 0.85 AOC3 (0.35) PIK3CGAOC3
SCHEMBL4877774 0.84 NPC1 (0.38) KDM4ESMN1; SMN2HTTRAB9ANPC1
SCHEMBL4986021 0.83 AOC3 (0.34) KMT2AKDM4EALDH1A1MEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7442715-B2 Thiazole derivatives ASTELLAS PHARMA INC. (JP) 2008-10-28 US disclosed
US-20060276521-A1 Thiazole derivatives ASTELLAS PHARMA INC. (JP) 2006-12-07 US disclosed
EP-1608365-A1 METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE Sucampo AG (CH) 2005-12-28 EP disclosed
WO-2004087138-A1 METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE SUCAMPO AG (CH) 2004-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276521-A1 Thiazole derivatives VCAM1, ICAM1, TXNL1 KMT2A 4395/4885PPARG 1095/4885NCOA2 1583/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.